Istraživanje New Cleveland Clinic po prvi put pokazuje da ibrutinib (ibrutinib) koji je odobrila FDA za limfom i leukemiju također može pomoći u liječenju najčešćih i smrtonosnih tumora mozga, te bi se jednog dana mogao koristiti kod pacijenata s glioblastomom i poboljšati stope preživljavanja.
Prema izvješću Američke udruge za tumore mozga, stopa preživljavanja glioblastoma je vrlo niska, a medijan preživljenja pacijenata koji primaju standardnu terapiju manji je od 15 mjeseci. Glioblastom je najsmrtonosniji primarni tumor mozga i vrlo je otporan na trenutne tretmane. Postoji hitna potreba da se tim pacijentima što prije osiguraju novi tretmani.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tumori in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
